Have you been diagnosed with esophageal cancer while taking oral bisphosphonates such as, – Fosamax, Actonel, Boniva, Atelvia, Didronel, or Skelid – for osteoporosis? The U.S. Food & Drug Administration (FDA) is currently conducting an ongoing safety review of oral osteoporosis drugs (bisphosphonates) of a possible link to esophageal cancer, a serious form of cancer that could be a side effect of oral bisphosphonate use.
The defective drug lawyers at Parker Waichman LLP are investigating potential lawsuits on behalf of esophageal cancer victims and other oral bisphosphonate side effects. If you or someone you care about developed esophageal cancer that might be associated with one of these drugs, you may be able to obtain compensation for your medical bills, lost wages, and pain and suffering by filing a bisphosphonate esophageal cancer lawsuit. To learn how our personal injury lawyers can help you, please contact us today.
Oral Bisphosphonates and Esophogeal Cancer Risk
Oral bisphosphonates include the drugs Fosamax, Actonel, Boniva, Atelvia, Didronel, and Skelid. Oral bisphosphonates are used for the prevention and treatment of osteoporosis, a disease that makes bones weak and prone to break, as well as other bone diseases such as Paget’s disease. One side effect of oral bisphosphonates is irritation of the esophagus, which can lead to esophagitis or esophageal ulcers, which may bleed.
The FDA is currently reviewing data from published studies to evaluate whether use of oral bisphosphonates is associated with an increased risk of esophageal cancer. According to a Drug Safety Communication issued by the agency on July 21, 2011, studies linking oral bisphosphonates to the development of esophageal cancer have been inconclusive so far. One of the largest studies reviewed by the FDA, a British study published in 2010, found that people taking oral bisphosphonates for more than five years may be doubling their risk of developing esophageal cancer. However, a second large study that drew data from the same British database found no increased risk.
In its communication, the FDA said it is unable to draw conclusions regarding the association between oral bisphosphonates and esophageal cancer, and for now, the agency continues to believe their benefits outweigh their risks.